ISR
There is no denying that large contract research organizations (CROs) are increasing their share of the outsourced drug development market. Preferred provider lists are dominated by the large CROs and it seems every week brings a new announcement of a "strategic partnership" between a large pharmaceutical company and a large CRO. However, one thing ISR has learned over the years of measuring delivery quality and loyalty is that being viewed as the "leader" does not guarantee a CRO a spot among the most favored. Similarly, record sales generation does not always translate to ensuring the most loyal customer base.
In ISR's new CRO Quality Benchmarking – Phase II/III Service Providers report, the data indicate the pendulum is swinging back toward the small or midsize CROs, at least from a delivery perspective (see chart below).
ISR is not suggesting that the large CROs possess disloyal, disgruntled customers Some are, in fact, quite strong. But four of the top five loyalty ratings in this year's Benchmarking study belong to small or midsize CROs.
The great news for study sponsors is they have choices. Whether the choice is driven by delivery quality, capabilities, relationship management, or something else, sponsors have viable options.
— Industry Standard Research
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.